Skip to content
Carbachol
Miostat (carbachol) is a small molecule pharmaceutical. Carbachol was first approved as Miostat on 1982-01-01. It is used to treat glaucoma in the USA. The pharmaceutical is active against muscarinic acetylcholine receptor M3. In addition, it is known to target muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M5, muscarinic acetylcholine receptor M1, and muscarinic acetylcholine receptor M4.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
eye diseasesD005128
Trade Name
FDA
EMA
Miostat (discontinued: Carbastat)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Carbachol
Tradename
Company
Number
Date
Products
MIOSTATAlcon ResearchN-016968 RX1982-01-01
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
miostat New Drug Application2020-11-09
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
glaucomaEFO_0000516D005901H40
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N07: Other nervous system drugs in atc
— N07A: Parasympathomimetics
— N07AB: Choline esters, parasympathomimetics
— N07AB01: Carbachol
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01E: Antiglaucoma preparations and miotics
— S01EB: Parasympathomimetics, antiglaucoma preparations and miotics
— S01EB02: Carbachol
HCPCS
No data
Clinical
Clinical Trials
135 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic renal insufficiencyD051436N181—27212
PsoriasisD011565EFO_0000676L401216212
Secondary hyperparathyroidismD006962EFO_1001173—115310
Vitamin d deficiencyD014808EFO_0003762E551—1259
Chronic kidney failureD007676EFO_0003884N18.6—2—237
Diabetic nephropathiesD003928EFO_0000401—12114
OsteoporosisD010024EFO_0003882M81.01—11—3
ProteinuriaD011507HP_0000093R80———3—3
Iga glomerulonephritisD005922EFO_0004194———112
Postmenopausal osteoporosisD015663EFO_00038541——1—2
Show 15 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic neoplasmsD011471C613102—114
HypocalcemiaD006996HP_0002901E83.51—31—26
Adenomatous polypsD018256D28——1——1
AngiofibromaD018322EFO_1001761——1——1
Heart transplantationD016027EFO_0010673——1——1
OsteopetrosisD010022Q78.2——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C5012——14
HypertensionD006973EFO_0000537I1011——13
Non-small-cell lung carcinomaD00228923———3
Castration-resistant prostatic neoplasmsD064129—2———2
Pancreatic neoplasmsD010190EFO_0003860C25—2———2
Crohn diseaseD003424EFO_0000384K5011——12
Myelodysplastic syndromesD009190D46—2———2
HypoparathyroidismD007011E20—1——12
Chronic kidney disease-mineral and bone disorderD012080EFO_1001152N25.0—2———2
Type 1 diabetes mellitusD003922EFO_0001359E10—2———2
Show 14 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C806————6
Healthy volunteers/patients—1————1
Cocaine-related disordersD019970F141————1
Hypophosphatemic ricketsD063730E83.311————1
Chronic diseaseD0029081————1
Ovarian neoplasmsD010051EFO_0003893C561————1
Endometrial neoplasmsD016889EFO_00042301————1
Uterine cervical neoplasmsD0025831————1
Central nervous system neoplasmsD0165431————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Open-angle glaucomaD005902EFO_0004190H40.1————22
Rheumatoid arthritisD001172EFO_0000685M06.9————11
Kidney diseasesD007674EFO_0003086N08————11
HyperparathyroidismD006961EFO_0008506E21.3————11
Thyroid diseasesD013959HP_0000820E00-E07————11
ObesityD009765EFO_0001073E66.9————11
Type 2 diabetes mellitusD003924EFO_0001360E11————11
Lung neoplasmsD008175C34.90————11
Tobacco use disorderD014029F17————11
Precancerous conditionsD011230————11
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCARBACHOL
INNcarbachol
Description
Carbachol is an ammonium salt and a carbamate ester. It has a role as a nicotinic acetylcholine receptor agonist, a muscarinic agonist, a non-narcotic analgesic, a cardiotonic drug and a miotic.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[N+](C)(C)CCOC(N)=O.[Cl-]
Identifiers
PDB—
CAS-ID51-83-2
RxCUI1999
ChEMBL IDCHEMBL14
ChEBI ID3385
PubChem CID5831
DrugBankDB00411
UNII ID8Y164V895Y (ChemIDplus, GSRS)
Target
Agency Approved
CHRM3
CHRM3
Organism
Homo sapiens
Gene name
CHRM3
Gene synonyms
NCBI Gene ID
Protein name
muscarinic acetylcholine receptor M3
Protein synonyms
acetylcholine receptor, muscarinic 3, m3 muscarinic receptor
Uniprot ID
Mouse ortholog
Chrm3 (12671)
muscarinic acetylcholine receptor M3 (Q9ERZ3)
Alternate
CHRM2
CHRM2
CHRM5
CHRM5
CHRM1
CHRM1
CHRM4
CHRM4
Organism
Homo sapiens
Gene name
CHRM2
Gene synonyms
NCBI Gene ID
Protein name
muscarinic acetylcholine receptor M2
Protein synonyms
7TM receptor, acetylcholine receptor, muscarinic 2, muscarinic M2 receptor
Uniprot ID
Mouse ortholog
Chrm2 (243764)
muscarinic acetylcholine receptor M2 (Q9ERZ4)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 15,254 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,125 adverse events reported
View more details